Surgery Insight: Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience

Joseph A. Dearani, Steve R. Ommen, Bernard J. Gersh, Hartzell V Schaff, Gordon K. Danielson

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Septal myectomy has been the gold standard treatment for the relief left ventricular outflow tract obstruction and cardiac symptoms in both adults and children with obstructive hypertrophic cardiomyopathy. In almost all circumstances, abnormalities of the mitral valve and subvalvar mitral apparatus can be managed without the need for mitral valve replacement, and other cardiac lesions can be repaired simultaneously. In the current era, the operative mortality for isolated septal myectomy at an experienced center is low in both children and adults (approximately 1%). Excellent late results with myectomy are gratifying: 90% of patients improve by at least one NYHA class, and improvements persist in most individuals on late follow-up. Late survival in patients with obstructive hypertrophic cardiomyopathy who undergo myectomy exceeds that of patients who do not receive surgical treatment and, in addition, myectomy may be associated with reduced long-term risk of sudden cardiac death. These results should serve as a basis for comparison with newer nonsurgical treatment regimens.

Original languageEnglish (US)
Pages (from-to)503-512
Number of pages10
JournalNature Clinical Practice Cardiovascular Medicine
Volume4
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Hypertrophic Cardiomyopathy
Mitral Valve
Ventricular Outflow Obstruction
Sudden Cardiac Death
Therapeutics
Survival
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Surgery Insight : Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience. / Dearani, Joseph A.; Ommen, Steve R.; Gersh, Bernard J.; Schaff, Hartzell V; Danielson, Gordon K.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 4, No. 9, 09.2007, p. 503-512.

Research output: Contribution to journalArticle

Dearani, Joseph A. ; Ommen, Steve R. ; Gersh, Bernard J. ; Schaff, Hartzell V ; Danielson, Gordon K. / Surgery Insight : Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience. In: Nature Clinical Practice Cardiovascular Medicine. 2007 ; Vol. 4, No. 9. pp. 503-512.
@article{a51dc59adf104893a121997c2e9e8e3e,
title = "Surgery Insight: Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience",
abstract = "Septal myectomy has been the gold standard treatment for the relief left ventricular outflow tract obstruction and cardiac symptoms in both adults and children with obstructive hypertrophic cardiomyopathy. In almost all circumstances, abnormalities of the mitral valve and subvalvar mitral apparatus can be managed without the need for mitral valve replacement, and other cardiac lesions can be repaired simultaneously. In the current era, the operative mortality for isolated septal myectomy at an experienced center is low in both children and adults (approximately 1{\%}). Excellent late results with myectomy are gratifying: 90{\%} of patients improve by at least one NYHA class, and improvements persist in most individuals on late follow-up. Late survival in patients with obstructive hypertrophic cardiomyopathy who undergo myectomy exceeds that of patients who do not receive surgical treatment and, in addition, myectomy may be associated with reduced long-term risk of sudden cardiac death. These results should serve as a basis for comparison with newer nonsurgical treatment regimens.",
author = "Dearani, {Joseph A.} and Ommen, {Steve R.} and Gersh, {Bernard J.} and Schaff, {Hartzell V} and Danielson, {Gordon K.}",
year = "2007",
month = "9",
doi = "10.1038/ncpcardio0957",
language = "English (US)",
volume = "4",
pages = "503--512",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Surgery Insight

T2 - Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience

AU - Dearani, Joseph A.

AU - Ommen, Steve R.

AU - Gersh, Bernard J.

AU - Schaff, Hartzell V

AU - Danielson, Gordon K.

PY - 2007/9

Y1 - 2007/9

N2 - Septal myectomy has been the gold standard treatment for the relief left ventricular outflow tract obstruction and cardiac symptoms in both adults and children with obstructive hypertrophic cardiomyopathy. In almost all circumstances, abnormalities of the mitral valve and subvalvar mitral apparatus can be managed without the need for mitral valve replacement, and other cardiac lesions can be repaired simultaneously. In the current era, the operative mortality for isolated septal myectomy at an experienced center is low in both children and adults (approximately 1%). Excellent late results with myectomy are gratifying: 90% of patients improve by at least one NYHA class, and improvements persist in most individuals on late follow-up. Late survival in patients with obstructive hypertrophic cardiomyopathy who undergo myectomy exceeds that of patients who do not receive surgical treatment and, in addition, myectomy may be associated with reduced long-term risk of sudden cardiac death. These results should serve as a basis for comparison with newer nonsurgical treatment regimens.

AB - Septal myectomy has been the gold standard treatment for the relief left ventricular outflow tract obstruction and cardiac symptoms in both adults and children with obstructive hypertrophic cardiomyopathy. In almost all circumstances, abnormalities of the mitral valve and subvalvar mitral apparatus can be managed without the need for mitral valve replacement, and other cardiac lesions can be repaired simultaneously. In the current era, the operative mortality for isolated septal myectomy at an experienced center is low in both children and adults (approximately 1%). Excellent late results with myectomy are gratifying: 90% of patients improve by at least one NYHA class, and improvements persist in most individuals on late follow-up. Late survival in patients with obstructive hypertrophic cardiomyopathy who undergo myectomy exceeds that of patients who do not receive surgical treatment and, in addition, myectomy may be associated with reduced long-term risk of sudden cardiac death. These results should serve as a basis for comparison with newer nonsurgical treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=34548293005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548293005&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio0957

DO - 10.1038/ncpcardio0957

M3 - Article

C2 - 17712363

AN - SCOPUS:34548293005

VL - 4

SP - 503

EP - 512

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 9

ER -